• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.延迟肾切除术对直径大于4cm肾肿瘤患者肿瘤学结局的影响。
Urol Oncol. 2016 May;34(5):239.e1-8. doi: 10.1016/j.urolonc.2015.12.001. Epub 2016 Jan 12.
2
The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma.延迟 II 期或更高分期肾细胞癌根治性肾切除术的影响。
J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7. doi: 10.1007/s00432-012-1230-2. Epub 2012 May 1.
3
Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者减瘤性部分肾切除术的使用趋势及其对总生存期的影响
Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.
4
The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.基于肾肿瘤大小的侵袭性与惰性组织学概率:对监测和治疗的影响。
Eur Urol. 2018 Oct;74(4):489-497. doi: 10.1016/j.eururo.2018.06.003. Epub 2018 Jul 13.
5
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.部分和根治性肾切除术治疗良性肾肿瘤患者的 IV 期慢性肾脏病的总生存和发展。
Eur Urol. 2013 Oct;64(4):600-6. doi: 10.1016/j.eururo.2012.12.023. Epub 2012 Dec 25.
6
Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.临床T1期肾细胞癌行部分肾切除术后偶然病理分期为T3a期的多机构生存分析
Urology. 2018 Jul;117:95-100. doi: 10.1016/j.urology.2018.04.002. Epub 2018 Apr 17.
7
Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.透明细胞肾细胞癌中的淋巴管浸润——与无病生存和癌症特异性生存相关。
Urol Oncol. 2014 Jan;32(1):30.e23-8. doi: 10.1016/j.urolonc.2012.11.002. Epub 2013 Feb 18.
8
Significance of Pathologic T3a Upstaging in Clinical T1 Renal Masses Undergoing Nephrectomy.接受肾切除术的临床T1期肾肿块中病理T3a分期上调的意义
Clin Genitourin Cancer. 2015 Aug;13(4):344-349. doi: 10.1016/j.clgc.2015.01.001. Epub 2015 Jan 22.
9
Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?对于小肾癌,行肾脏肿瘤活检是否会增加最终手术病理报告的升级风险和复发风险?
Urol Oncol. 2020 Oct;38(10):798.e9-798.e16. doi: 10.1016/j.urolonc.2020.06.001. Epub 2020 Jul 18.
10
Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice.在癌症委员会认可的机构接受治疗的 T1a 期肾细胞癌年轻患者中,部分肾切除术与根治性肾切除术的生存率比较以及合并症对治疗选择的影响。
Urol Oncol. 2017 Nov;35(11):660.e9-660.e15. doi: 10.1016/j.urolonc.2017.06.056. Epub 2017 Jul 20.

引用本文的文献

1
Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona.亚利桑那州社区社会脆弱性与肾癌手术治疗和生存时间差异
Cancer Med. 2024 Feb;13(3):e7007. doi: 10.1002/cam4.7007.
2
Impact of Time-To-Surgery on the Prognosis of Patients with T1 Renal Cell Carcinoma: Implications for the COVID-19 Pandemic.手术时间对T1期肾细胞癌患者预后的影响:对COVID-19大流行的启示
J Clin Med. 2022 Dec 19;11(24):7517. doi: 10.3390/jcm11247517.
3
Can We Identify Patients in Danger of Delayed Treatment? Management of COVID-19 Pandemic Backlog in Urology Care in Poland.能否识别可能延迟治疗的患者?波兰泌尿科 COVID-19 积压病例管理。
Int J Environ Res Public Health. 2022 Dec 9;19(24):16547. doi: 10.3390/ijerph192416547.
4
Association between COVID-19 Burden, Population Vaccination Status, and Urologic Oncology Surgery Volume: A National Multicenter Cross-Sectional Study.2019冠状病毒病负担、人群疫苗接种状况与泌尿外科肿瘤手术量之间的关联:一项全国多中心横断面研究
J Clin Med. 2022 Nov 29;11(23):7071. doi: 10.3390/jcm11237071.
5
An external validation of the nocera nomogram: Predicting non-organ confined stage of ≥pT3 in cT1 clear cell renal cell carcinoma.诺切拉列线图的外部验证:预测cT1期透明细胞肾细胞癌中≥pT3的非器官局限性分期
Front Oncol. 2022 Oct 10;12:1019057. doi: 10.3389/fonc.2022.1019057. eCollection 2022.
6
Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics.术前手术等待时间和肾细胞癌肿瘤特征方面的种族和族裔差异。
Healthcare (Basel). 2021 Sep 8;9(9):1183. doi: 10.3390/healthcare9091183.
7
Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC.从诊断起肾切除延迟超过10周与pT3期肾细胞癌的总生存期降低相关。
J Kidney Cancer VHL. 2021 Jun 14;8(2):27-33. doi: 10.15586/jkcvhl.v8i2.125. eCollection 2021.
8
What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.2019冠状病毒病时期的择期肿瘤手术是什么?关于手术延迟对癌症患者预后影响的文献综述
Clin Oncol Res. 2020 Jun;3(6):1-11. doi: 10.31487/j.COR.2020.06.05. Epub 2020 Jun 26.
9
Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic.局部和转移性肾细胞癌延迟手术:COVID-19 大流行的系统评价和荟萃分析。
World J Urol. 2021 Dec;39(12):4295-4303. doi: 10.1007/s00345-021-03734-1. Epub 2021 May 24.
10
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.由于 COVID-19,新诊断癌症患者的延迟治疗以及对法国癌症死亡率的估计影响。
ESMO Open. 2021 Jun;6(3):100134. doi: 10.1016/j.esmoop.2021.100134. Epub 2021 Apr 17.

本文引用的文献

1
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南:肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.
2
Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance.主动监测下 cT1b 和 cT2 期肾肿块的生长动力学和短期结果。
J Urol. 2014 Sep;192(3):659-64. doi: 10.1016/j.juro.2014.03.038. Epub 2014 Mar 15.
3
Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage.手术治疗肾细胞癌的组织病理学:亚型和分期的生存差异。
J Urol. 2012 Aug;188(2):391-7. doi: 10.1016/j.juro.2012.04.006. Epub 2012 Jun 13.
4
The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma.延迟 II 期或更高分期肾细胞癌根治性肾切除术的影响。
J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7. doi: 10.1007/s00432-012-1230-2. Epub 2012 May 1.
5
Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data.直径≤7cm 肾细胞癌的转移潜能:瑞典肾癌质量登记数据。
Eur Urol. 2011 Nov;60(5):975-82. doi: 10.1016/j.eururo.2011.06.029. Epub 2011 Jul 1.
6
Landmark analysis at the 25-year landmark point.在25年时间节点进行的标志性分析。
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71. doi: 10.1161/CIRCOUTCOMES.110.957951.
7
Metastatic potential of a renal mass according to original tumour size at presentation.根据初诊时原发肿瘤的大小判断肾肿瘤的转移潜能。
BJU Int. 2012 Jan;109(2):190-4; discussion 194. doi: 10.1111/j.1464-410X.2011.10184.x. Epub 2011 May 9.
8
Active surveillance of small renal masses: progression patterns of early stage kidney cancer.小肾肿瘤的主动监测:早期肾癌的进展模式。
Eur Urol. 2011 Jul;60(1):39-44. doi: 10.1016/j.eururo.2011.03.030. Epub 2011 Apr 1.
9
Wait times for cancer surgery in the United States: trends and predictors of delays.美国癌症手术的等待时间:延迟的趋势和预测因素。
Ann Surg. 2011 Apr;253(4):779-85. doi: 10.1097/SLA.0b013e318211cc0f.
10
How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?肾细胞癌患者在不影响病理结果的情况下可以等待多久进行手术?
Can Urol Assoc J. 2011 Dec;5(6):E148-51. doi: 10.5489/cuaj.10035. Epub 2011 Mar 1.

延迟肾切除术对直径大于4cm肾肿瘤患者肿瘤学结局的影响。

The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.

作者信息

Mano Roy, Vertosick Emily A, Hakimi Abraham Ari, Sternberg Itay A, Sjoberg Daniel D, Bernstein Melanie, Dalbagni Guido, Coleman Jonathan A, Russo Paul

机构信息

Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Urol Oncol. 2016 May;34(5):239.e1-8. doi: 10.1016/j.urolonc.2015.12.001. Epub 2016 Jan 12.

DOI:10.1016/j.urolonc.2015.12.001
PMID:26795607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4834237/
Abstract

OBJECTIVES

Delaying nephrectomy<3 months does not adversely affect treatment outcome of renal tumors. Whether surgical waiting time (SWT; time from diagnosis to surgery)>3 months affects treatment outcome for large renal masses has not been well studied. We aimed to evaluate if SWT is associated with treatment outcome of renal masses >4cm and identify patients who are more likely to experience prolonged SWT.

MATERIALS AND METHODS

Data from 1,484 patients undergoing radical or partial nephrectomy at a single institution for a nonmetastatic renal mass>4cm between 1995 and 2013 were reviewed. Patients with benign tumors and incomplete preoperative data were excluded. The association between SWT and disease upstaging at the time of surgery and recurrence at 2 and 5 years was assessed using logistic regression. Cancer-specific survival (CSS) and overall survival were assessed with landmark survival analyses and multivariable Cox proportional hazards models. All analyses were adjusted for patient and tumor characteristics.

RESULTS

Of the final cohort of 1,278 patients, 267 (21%) had SWT>3 months. Patients with larger, symptomatic tumors had shorter SWT. Median follow-up for survivors was 3.8 years (interquartile range: 1.5-7.4). On multivariable analysis, SWT was not associated with disease upstaging, recurrence, or CSS. Longer SWT was associated with decreased overall survival (hazard ratio = 1.17; 95% CI: 1.08-1.27; P = 0.0002). Sex and tumor size, histology, and presentation were associated with disease upstaging, recurrence, and CSS. The most common cause for surgical delay>3 months was evaluation and treatment of comorbidities.

CONCLUSION

Patient and tumor characteristics, rather than SWT, were associated with disease upstaging, recurrence, and CSS, and should guide the decision to delay surgery when treating nonmetastatic renal tumors>4cm.

摘要

目的

将肾切除术推迟至<3个月对肾肿瘤的治疗结果并无不利影响。手术等待时间(SWT;从诊断到手术的时间)>3个月是否会影响大型肾肿块的治疗结果尚未得到充分研究。我们旨在评估SWT是否与直径>4cm的肾肿块的治疗结果相关,并确定更有可能经历较长SWT的患者。

材料与方法

回顾了1995年至2013年间在单一机构接受根治性或部分肾切除术的1484例患者的数据,这些患者患有直径>4cm的非转移性肾肿块。排除患有良性肿瘤和术前数据不完整的患者。使用逻辑回归评估SWT与手术时疾病分期升级以及2年和5年复发之间的关联。通过标志性生存分析和多变量Cox比例风险模型评估癌症特异性生存(CSS)和总生存。所有分析均针对患者和肿瘤特征进行了调整。

结果

在最终的1278例患者队列中,267例(21%)的SWT>3个月。肿瘤较大且有症状的患者SWT较短。幸存者的中位随访时间为3.8年(四分位间距:1.5 - 7.4)。在多变量分析中,SWT与疾病分期升级、复发或CSS无关。较长的SWT与总生存降低相关(风险比 = 1.17;95%可信区间:1.08 - 1.27;P = 0.0002)。性别、肿瘤大小、组织学和临床表现与疾病分期升级、复发和CSS相关。手术延迟>3个月的最常见原因是合并症的评估和治疗。

结论

患者和肿瘤特征而非SWT与疾病分期升级、复发和CSS相关,在治疗直径>4cm的非转移性肾肿瘤时,应指导手术延迟的决策。